R&D and Medical Affairs Careers
Concentrated resources strengthen our presence in the pharmaceutical market and help us meet highly competitive goals, further enhancing Eisai’s commitment as a human health care (hhc) company.
An innovative end-to-end business model efficiently integrates discovery, clinical and commercial functions to support our unmatched pipeline in neuroscience oncology, and antibody-based programs. Forward-thinking candidates who are dedicated to advancing patient care have the opportunity to embark on diverse and expansive career paths in these areas:
Eisai’s efforts are centered on dementia prevention and cure via the next-generation Alzheimer’s disease treatments now under development. We are also pursuing a new insomnia treatment, as well as expanded indications and new formulations for existing products. Current neurology R&D initiatives include:
Early and Minimally Invasive Diagnostics
Novel Neuro-Transmission Pathways
Neuro Inflammation and Immuno-Genetics
We are currently exploring more than one dozen molecules, formulations, and combinations in 20+ clinical trials. Current oncology R&D initiatives include:
- Mesenchymal Cells and Stromal Cells (Cell Differentiation and Cancer Stemness)
- Myeloid Cells (Immunosuppressive Myeloid Lineage)
- Endothelial Cells (Abnormal Tumor Vessels)
Cancer Cells – Driver Gene Mutation and Aberrant Splicing
Andover innovative Medicines (AiM) Institute
This Eisai Discovery Innovation Unit engages quantitative, biological, chemistry, and translational scientists in the integrated discovery and development of precision medicines for dementia, cancer, and auto-immune diseases.
Our emphasis is on ownership of a focused portfolio by a group of passionate scientists that all belong to a single organization with a common mission. We also look for opportunities to strengthen and build strategic scientific partnerships and alliances that complement our areas of expertise.
This unprecedented level of multi-sector collaboration – from pre-competitive research consortia to the shared publication of studies – enables flexible business models and agreements that help accelerate the delivery of new medicines to patients. AiM initiatives are targeted on: